The US Food and Drug Administration (FDA) has approved Ferring Pharmaceuticals’ adenovirus vector-based gene therapy, Adstiladrin (nadofaragene firadenovec-vncg). Adstiladrin is an intravesical therapy administered to the patient at three-month intervals. The therapy is used to treat adults with high-risk Bascillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) that works by targeting the individuals’ bladder wall cells to boost the body’s natural defenses to fight cancer. According to the firm, the FDA approval is based on positive Phase III clinical trial…